Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).
Comments Off on Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).
April 28, 2026
A phase 2 open-label trial evaluated transdermal CBD for 22q11.2 deletion syndrome in children, demonstrating tolerability with preliminary behavioral improvements. While promising for this rare genetic condition, controlled trials are needed to…
Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).
Comments Off on Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).
March 27, 2026
CED Clinical Relevance #64Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch | CED Clinic CbdPediatricNeurodevelopmentalTransdermalOpen-Label…
Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
Comments Off on Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
March 4, 2026
Clinical Takeaway Transdermal cannabidiol gel (ZYN002) has been studied in children and adolescents with Fragile X syndrome through an open-label extension trial focused on long-term safety and tolerability. Early interim data suggest the synthetic CBD…